Inogen, Inc (INGN) News

Inogen, Inc (INGN): $41.77

0.03 (+0.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter INGN News Items

INGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

INGN News Highlights

  • For INGN, its 30 day story count is now at 4.
  • Over the past 22 days, the trend for INGN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • MD are the most mentioned tickers in articles about INGN.

Latest INGN News From Around the Web

Below are the latest news stories about Inogen Inc that investors may wish to consider to help them evaluate INGN as an investment opportunity.

Inogen to Announce Third Quarter 2021 Financial Results on November 4, 2021

GOLETA, Calif., October 13, 2021--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release third quarter 2021 financial results after market close on Thursday, November 4, 2021. The Company will host a corresponding conference call beginning at 2:00pm PT/5:00pm ET.

Yahoo | October 13, 2021

Inogen Appoints Stanislav Glezer as Chief Technology Officer

GOLETA, Calif., October 12, 2021--Inogen, Inc. (NASDAQ: INGN), ("Inogen" or "the Company"), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that Stanislav Glezer, MD has been appointed to the role of Chief Technology Officer responsible for R&D and Engineering, Medical Affairs, and Regulatory Affairs. Mr. Glezer will remain an Executive Vice President of the Company.

Yahoo | October 12, 2021

Here's Why You Should Retain Inogen (INGN) Stock For Now

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Yahoo | September 21, 2021

Inogen Strengthens Commercial Capabilities Through New Ashfield Relationship

GOLETA, Calif., September 21, 2021--Inogen, Inc. (NASDAQ: INGN), ("Inogen" or "the Company"), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced an agreement to enhance its go-to-market capabilities with Ashfield Healthcare, LLC, part of UDG Healthcare ("Ashfield").

Yahoo | September 21, 2021

Inogen (INGN) Shareholder Litigation Alert: Should Inogen Management be Held Accountable for Investors Losses? Contact Johnson Fistel, LLP Regarding Pending Derivative Case

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, the court-appointed Lead Counsel in a derivative action brought for the benefit of Inogen, Inc. (NASDAQ: INGN) and its shareholders, announces today that a securities fraud class action pending before U.S. District Judge Fernando M. Olguin in the Central District of California against Inogen, captioned In re Inogen, Inc. Sec. Litig. , No. CV 19-1643, remains alive despite Judge Olguins August 13, 2021 order granting the defendants motion to dismiss the case. Recognizing the formidable pleading standards that plaintiffs must meet to state a federal securities claim, Judge Olguin gave the plaintiff shareholders leave to amend their claims against the defendants and to file another complaint.

Intrado Digital Media | September 2, 2021

US Biosimilars Market to Hit USD 30.83 Billion with by 2028; Rising Population Suffering from Chronic Diseases to Augment Growth: Fortune Business Insights

Top Players Covered in the US Biosimilars Market Research Report are Pfizer Inc. (New York, U.S.), Samsung Bioepis (Incheon, South Korea), Celltrion Inc. (Incheon, South Korea), Novartis AG (Basel, Switzerland), Inogen (Goleta, U.S.), Amgen Inc. (California, U.S.), Mylan N.V. (Pennsylvania, US.), Coherus BioSciences (California, U.S.), and other key market players Top Players Covered in the US Biosimilars Market Research Report are Pfizer Inc. (New York, U.S.), Samsung Bioepis (Incheon, South Korea), Celltrion Inc. (Incheon, South Korea), Novartis AG (Basel, Switzerland), Inogen (Goleta, U.S.), Amgen Inc. (California, U.S.), Mylan N.V. (Pennsylvania, US.), Coherus BioSciences (California, U.S.), and other key market players

Intrado Digital Media | August 30, 2021

Global Oxygen Concentrator Market Outlook 2021-2026 with Teijin, Nidek Medical Products, Inogen, ResMed, and Invacare Dominating

Dublin, Aug. 12, 2021 (GLOBE NEWSWIRE) -- The "Global Oxygen Concentrator Market Outlook, 2026" report has been added to ResearchAndMarkets.com''s offering. With the demand for medical oxygen continuing unabated and countries struggling to keep pace with demand, the oxygen concentrator has emerged as a sought-after device. The high demand for medical oxygen concentrators is mainly attributed to infections and chronic diseases affecting the respiratory health of individuals. The major use of oxygen was prominent with the incline in the respiratory issues caused by increasing pollution, resulting in a market value of USD 1.59 Billion in 2015.

Intrado Digital Media | August 12, 2021

Inogen stock suffers record plunge as chip shortage to hurt sales, margins for another year

Chief Executive Nabil Shabshab said demand for POCs and pricing has been strong, given higher rates of vaccination for COVID-19 and an “increased desire for mobility” as pandemic-related restrictions have been lifted. Read more about the chip shortage.

Yahoo | August 6, 2021

Inogen (INGN) Stock Loses 26.7% In Spite of Q2 Earnings Beat

Inogen's (INGN) second-quarter results benefit from higher revenues across its segments.

Yahoo | August 6, 2021

Inogen Stock Plunges As Supply Chain Constraints Pile Up To Hit 2H FY21; Analysts Downgrade Stock

Inogen Inc (NASDAQ: INGN ) reported Q2 revenue of $101.6 million , +41.7% Y/Y, beating the consensus of $88.75 million. The sales growth was driven primarily due to strong consumer demand, improved average selling prices in all channels, and reduced COVID-19 pandemic-related impacts. The Company reported domestic direct-to-consumer revenue of $40.9 million, a 35.6% increase. Rental revenue was $11.3 million, an 85.2% increase. We are pleased with our recovery in our core business. Demand and average selling prices for portable oxygen concentrators increased primarily due to higher consumer confidence and higher Full story available on Benzinga.com

Benzinga | August 5, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 3.2293 seconds.